Treatments using anti-RANKL, anti-TNF, or anti-IL-6 receptor aiming at decreasing the high level of these pro-osteoclastogenic cytokines, do not reverse bone formation inhibition in RA patients under therapy [116]. Here, TNF is linked to rheumatoid arthritis.